Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabeth Botelho-Nevers

Showing results (111-120 of 113) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 113 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Scientific Reports|April 24, 2025
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M Smadja, Clément R Massonnaud, Aurélien Philippe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Pageof 12

Showing results (111-120 of 113) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 113 results.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|December 21, 2025
Accuracy of VIDAS® TB-IGRA in TB patients and individuals with different thresholds of exposureDelia Goletti, Niaz Banaei, Rahul Batra, et al.
Scientific Reports|April 24, 2025
sST2 is a key outcome biomarker in COVID-19: insights from discovery randomized trialDavid M Smadja, Clément R Massonnaud, Aurélien Philippe, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 28, 2021
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19Florence Ader, Nathan Peiffer-Smadja, Julien Poissy, et al.
Pageof 12